{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pinal-Fernandez I"],"funding":["National Institute of Arthritis and Musculoskeletal and Skin Diseases","National Institute of Environmental Health Sciences","Intramural NIH HHS","NIEHS NIH HHS","Myositis Association","NIAMS NIH HHS","The Myositis Association"],"pagination":["358-364"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8792092"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["74(2)"],"pubmed_abstract":["<h4>Objective</h4>To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.<h4>Methods</h4>In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared.<h4>Results</h4>Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti-Mi-2 autoantibodies (24%; P = 0.03) or anti-NXP-2 autoa"],"journal":["Arthritis & rheumatology (Hoboken, N.J.)"],"pubmed_title":["Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis."],"pmcid":["PMC8792092"],"funding_grant_id":["ZIA AR041203"],"pubmed_authors":["Siegel D","Albayda J","Rosenkranz M","Nanda K","Lloyd TE","DeGuzman MM","Edelheit BS","Barillas-Arias L","Huber A","Bohnsack JF","Sabbagh S","George SW","Cartwright V","Vogelgesang SA","Ballinger S","Ebernardt BA","Casciola-Rosen L","Childhood Myositis Heterogeneity Collaborative Study Group","Ray LI","Higgins GC","Kingsbury DJ","Dare J","Baucells A","Rennebohm RM","Weiser P","Tiniakou E","Kimura Y","Cawkwell GD","Person DA","Curiel R","Miller FW","Arabshahi B","Shenoi S","Zhao Y","Inman C","Henrickson M","El-Hallak M","Casal-Dominguez M","Paik J","Pinal-Fernandez I","Christopher-Stine L","Hoftman A","Shaham B","Stoll M","Wargula JC","Schiffenbauer A","Ronis T","Zeft A","Jansen A","Smukler A","Eade K","Knibbe WP","Sundel R","Carrasco R","Milojevic D","Imundo L","Selva-O'Callaghan A","Sule SH","Wahezi D","Jung L","Schmeling H","Soep J","Goldmuntz EA","Tarvin S","Hong S","Modica R","Hobday P","Perez MD","Rothman D","Lang BA","Gil-Vila A","Mitchell SR","Derfoul A","Martinez-Carretero MA","Mammen AL","Leffler M","Tesher M","Zemel LS","O'Hanlon T","Jarvis J","White PH","Graham B","Gottlieb B","Bingham CA","Kahn P","Pak K","Katona IM","Myers L","Pachman LM","Balboni I","Hannan W","Madson KL","Mamyrova G","Passo MH","Becker M","Rivas-Chacon RF","Lerman M","Sherry D","Weiss P","Nativ S","Volochayev R","Plotz B","Olson JC","Rider LG","Danoff SK","Finkel TH","Punaro MG","Lindsley CB"],"additional_accession":[]},"is_claimable":false,"name":"Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis.","description":"<h4>Objective</h4>To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.<h4>Methods</h4>In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared.<h4>Results</h4>Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti-Mi-2 autoantibodies (24%; P = 0.03) or anti-NXP-2 autoa","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-05-05T03:25:18.938Z","creation":"2025-04-05T09:05:56.996Z"},"accession":"S-EPMC8792092","cross_references":{"pubmed":["34313394"],"doi":["10.1002/art.41931"]}}